Abstract
Rhabdomyolysis is a syndrome due to a damage of skeletal muscle and the leakage of intracellular contents into the extracellular fluid and the circulation. Several causes may induce rhabdomyolysis and the major one is the crush syndrome. Most cases of non-traumatic rhabdomyolysis are related to drugs. Many molecules are subject to hepatic metabolism and the concomitant use of drugs, as statins, with other medications acting as substrates of the same isoenzymes can interact and increase the risk of myopathy.
Subclinical rise of creatine kinase may be the expression of rhabdomyolysis that can present as a medical emergency such as acute kidney injury (AKI), compartment syndrome, cardiac dysrhythmias and disseminated intravascular coagulopathy.
The main pathophysiological mechanisms of myoglobinuric-related AKI are renal vasoconstriction, formation of intraluminal casts and direct cytotoxicity promoted by heme-protein.
The aim of this review is to analyze the pathophysiology of myolysis, the causes of rhabdomyolysis and especially the link between the liver and the kidney, which can represent the connecting element for the development of the syndrome.
Keywords: Rhabdomyolysis, acute kidney injury, liver disease, drugs metabolism, statins.
Current Vascular Pharmacology
Title:Drugs and Rhabdomyolysis: From Liver to Kidney
Volume: 13 Issue: 6
Author(s): Biagio Barbano, Liborio Sardo, Maria L. Gasperini, Antonietta Gigante, Marta Liberatori, Gianluca G. Di Lazzaro, Francesca Di Mario, Barbara Dorelli, Antonio Amoroso and Rosario Cianci
Affiliation:
Keywords: Rhabdomyolysis, acute kidney injury, liver disease, drugs metabolism, statins.
Abstract: Rhabdomyolysis is a syndrome due to a damage of skeletal muscle and the leakage of intracellular contents into the extracellular fluid and the circulation. Several causes may induce rhabdomyolysis and the major one is the crush syndrome. Most cases of non-traumatic rhabdomyolysis are related to drugs. Many molecules are subject to hepatic metabolism and the concomitant use of drugs, as statins, with other medications acting as substrates of the same isoenzymes can interact and increase the risk of myopathy.
Subclinical rise of creatine kinase may be the expression of rhabdomyolysis that can present as a medical emergency such as acute kidney injury (AKI), compartment syndrome, cardiac dysrhythmias and disseminated intravascular coagulopathy.
The main pathophysiological mechanisms of myoglobinuric-related AKI are renal vasoconstriction, formation of intraluminal casts and direct cytotoxicity promoted by heme-protein.
The aim of this review is to analyze the pathophysiology of myolysis, the causes of rhabdomyolysis and especially the link between the liver and the kidney, which can represent the connecting element for the development of the syndrome.
Export Options
About this article
Cite this article as:
Barbano Biagio, Sardo Liborio, Gasperini L. Maria, Gigante Antonietta, Liberatori Marta, Di Lazzaro G. Gianluca, Di Mario Francesca, Dorelli Barbara, Amoroso Antonio and Cianci Rosario, Drugs and Rhabdomyolysis: From Liver to Kidney, Current Vascular Pharmacology 2015; 13 (6) . https://dx.doi.org/10.2174/1570161113666150130151839
DOI https://dx.doi.org/10.2174/1570161113666150130151839 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of Model-Based Approaches to Evaluate Hepatic Transporter-Mediated Drug Clearance: In vitro, In vivo, and In vitro-In vivo Extrapolation
Current Drug Metabolism Pharmacokinetic Considerations of Perinatal Antiretroviral Therapy
Current Drug Metabolism Intrauterine Intervention for the Treatment of Fetal Growth Restriction
Current Pediatric Reviews Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View
Current Neuropharmacology The Lung Disease of Rheumatoid Arthritis
Current Respiratory Medicine Reviews Host Innate Immune Responses to Microbial Pathogens
Current Vascular Pharmacology A Review on Skin Targeted Delivery of Bioactives as Ultradeformable Vesicles: Overcoming the Penetration Problem
Current Drug Targets Crosstalk between Inflammation and Coagulation: The Lessons of Sepsis
Current Vascular Pharmacology Role of Free Radicals in Sepsis: Antioxidant Therapy
Current Pharmaceutical Design Protein Bioinformatics Applied to Virology
Current Protein & Peptide Science Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Sigma-2 Receptor as a Potential Drug Target
Current Medicinal Chemistry The Association between Metabolic Syndrome and Serum Levels of Adiponectin and High Sensitive C Reactive Protein in Gorgan
Endocrine, Metabolic & Immune Disorders - Drug Targets Dietary Phytoestrogens: Neuroprotective Role in Parkinson’s Disease
Current Neurovascular Research Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management
Current Pharmaceutical Design Local Inflammation in Chronic Upper Airway Disease
Current Pharmaceutical Design Pharmacogenetic Applications of the Post Genomic Era
Current Pharmaceutical Biotechnology Interaction Between Bone and Muscle in Older Persons with Mobility Limitations
Current Pharmaceutical Design Dengue: Recent Advances in Biology and Current Status of Translational Research
Current Molecular Medicine Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets